The Cyclooxygenase-2 Inhibitor Nimesulide, a Nonsteroidal Analgesic, Decreases the Effect of Radiation Therapy in Head-and-Neck Cancer Cells

The Cyclooxygenase-2 Inhibitor Nimesulide, a Nonsteroidal Analgesic, Decreases the Effect of Radiation Therapy in Head-and-Neck Cancer Cells
复制标题

DOI:
10.1007/s00066-009-1929-4
复制
发表时间:
2009-05
影响因子:
3.1
通讯作者:
C. Czembirek;C. Eder-Czembirek;B. Erovic;D. Turhani;A. Spittler;E. Selzer;R. Pötter;D. Thurnher
C. Czembirek;C. Eder-Czembirek;B. Erovic;D. Turhani;A. Spittler;E. Selzer;R. Pötter;D. Thurnher
中科院分区:
医学2区
文献类型:
--
作者:
C. Czembirek;C. Eder-Czembirek;B. Erovic;D. Turhani;A. Spittler;E. Selzer;R. Pötter;D. Thurnher

文献摘要

被引文献

相似文献

背景:目前尚无关于环氧化酶-2(考克斯-2)抑制剂尼美舒利联合放疗对头颈癌细胞存活的影响的资料。材料与方法:用尼美舒利(50-600 μM)处理两种头颈癌细胞系(SCC 9和SCC 25),同时或依次照射。通过计数细胞数量研究对细胞存活的早期影响,通过集落形成试验研究长期影响。细胞周期的影响进行了分析后24-72小时尼美舒利治疗通过流式cytometry.Results:出乎意料的是,尼美舒利单独抑制细胞增殖,而不影响集落形成能力。此外,在短期试验中没有发现尼美舒利放射增敏作用的证据。尼美舒利单独或与radiation.Conclusion结合对克隆生存没有影响:尼美舒利差异影响细胞增殖和克隆生存,并可能降低放疗的疗效。评估肿瘤生长的短期试验可能无法正确预测考克斯-2抑制剂的临床相关长期效应。
Background:No data are available on the effects of the cyclooxygenase-2 (COX-2) inhibitor nimesulide in combination with irradiation on the survival of head-and-neck carcinoma cells.Material and Methods:Two head-and-neck carcinoma cell lines (SCC9 and SCC25) were treated with nimesulide (50–600 μM) and irradiated concomitantly or sequentially. Early effects on cell survival were investigated by counting cell numbers, long-term effects by colony-forming assays. Cell-cycle effects were analyzed 24–72 h after treatment with nimesulide by flow cytometry.Results:Unexpectedly, nimesulide solely inhibited cell proliferation without affecting colony-forming ability. In addition, no evidence for a radiosensitizing effect of nimesulide in short-term assays was seen. Nimesulide alone had no effect on clonogenic survival alone or in combination with radiation.Conclusion:Nimesulide differentially affects cell proliferation and clonogenic survival and may decrease the efficacy of radiotherapy. Short-term assays to assess tumor growth may not correctly predict the clinically relevant long-term effect of COX-2 inhibitors.